Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpha Cognition Inc. - Common Stock (NQ:ACOG)

8.320 -0.020 (-0.24%)
Delayed Quote Updated: 10:05 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alpha Cognition Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate... 
Via Newsfile
Topics Intellectual Property
News headline image
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 15, 2025 ↗
 
Via Benzinga
News headline image
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference
From Alpha Cognition
Via Business Wire
News headline image
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
From Alpha Cognition Inc.
Via Business Wire
News headline image
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on... 
Via Newsfile
Topics Intellectual Property
News headline image
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 31, 2025 ↗
 
Via Benzinga
News headline image
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst ↗
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm. 
Via Benzinga
News headline image
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
From Alpha Cognition Inc.
Via Business Wire
News headline image
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)
Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on... 
Via Newsfile
News headline image
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
From OTC Markets
Via GlobeNewswire
News headline image
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China ↗
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits for blast-related brain injuries. 
Via Benzinga
News headline image
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China
From Alpha Cognition, Inc.
Via Business Wire
News headline image
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Partial Exercise of Over-allotment Option
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Voluntary Delisting from CSE
From Alpha Cognition Inc.
Via Business Wire
News headline image
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
News headline image
Invizyne Technologies Jumps After IPO ↗
Invizyne Technologies opened on Nov. 13 at $11.10. Shares gained as much as 13% following the company's $15 million initial public offering. Additionally, Alpha Cognition opened on Nov. 12 at $7.00. 
Via Talk Markets
News headline image
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.